R
301333
vs
S
Shanghai Composite
Over the past 12 months, R&G PharmaStudies Co Ltd has outperformed Shanghai Composite, delivering a return of +44% compared to the Shanghai Composite's +27% growth.
Stocks Performance
301333 vs Shanghai Composite
Performance Gap
301333 vs Shanghai Composite
Performance By Year
301333 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
R&G PharmaStudies Co Ltd
Glance View
R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.
